INTRODUCTION
============

Recombinant human erythropoietin (rHu-EPO) is a 30,400-Dalton, 165-amino-acid glycosylated protein having more than 40% carbohydrate contents by mass ([@b5-molcell-37-11-819]). rHu-EPO has been used for the treatment of the anemia associated with chronic renal failure over a decade ([@b8-molcell-37-11-819]; [@b15-molcell-37-11-819]). The mode of action for the treatment with rHu-EPO is well-understood. The binding of EPO to specific receptors on cell surface triggers intracellular signaling pathways and results in the proliferation and differentiation of cells, and finally to an increase in haematocrit ([@b11-molcell-37-11-819]).

The interaction between EPO and its receptor is well-characterized by structural determinations using nuclear magnetic resonance (NMR) spectroscopy ([@b4-molcell-37-11-819]) and X-ray crystallography ([@b12-molcell-37-11-819]). These studies have proposed the potential amino acids involved in the interactions between EPO and its receptor. There are two binding sites for those interactions. Residues involved in the binding site 1 of EPO are Thr44 and Asn147 hydrogen bonded to the Phe93 of the receptor, and Arg10 and Arg14 of EPO interacting with Met150 of the receptor ([@b12-molcell-37-11-819]).

Any chemical or post-translational modification on amino acids of EPO in the binding sites invariably affects interactions between the EPO and its receptor and may result in lower EPO therapeutic efficacy. In the case of EPO, glycosylation has been well-documented as a post-translational modification. The N-glycosylations are important factors for the stability, pharmacokinetics, and biological activity of EPO ([@b6-molcell-37-11-819]; [@b13-molcell-37-11-819]). However, other modifications have not been well-investigated because of the complex isoform profiles of EPO due to glycosylation.

Biopharmaceuticals are highly complex protein molecules and may have some types of modification during upstream and downstream processes. These changes may influence the safety, purity, potency, and strength of products, which must be well-characterized, controlled, and monitored as part of the manufacturing process ([@b10-molcell-37-11-819]; [@b14-molcell-37-11-819]). In the case of EPO, the quality of four different products has been investigated and compared using several bioanalytical techniques ([@b2-molcell-37-11-819]). All products showed differences in terms of content and potency with the differences in isoform profiles resulting from distinct glycosylation ([@b2-molcell-37-11-819]). It's been suggested that monitoring of product quality is needed using physicochemical and biological analysis ([@b2-molcell-37-11-819]).

For the focused characterization of modifications in EPO, we investigated modifications on the binding sites between EPO and its receptor which may affect the efficacy of EPO. To get detailed information on the interface of EPO and its receptor, we first identified and visualized amino acids involved in the interaction between EPO and its receptor. Afterwards, a UPLC/Q-TOF method was used to evaluate the modifications on the amino acids. This study led to the identification of several modifications on the interface of EPO and its receptor including Asn47, Met54, and Asn147 localized on the binding site 1.

MATERIALS AND METHODS
=====================

Materials
---------

EPO BRP (EDQM, Ph. Eur.) contains a freeze-dried preparation of erythropoietin in vials with a declared content of 250 μg of erythropoietin per vial. This erythropoietin BRP is known as a 50:50 mixture of epoetin alfa (The R.W. Johnson pharmaceutical Research Institute) and epoetin beta (Boehringer-Mannheim, recently Roche).

Endoproteinase trypsin was purchased from Roche. Sodium phosphate, monobasic and dibasic, DTT, and guanidine-HCl were purchased from Sigma. Acetonitrile (ACN), TFA and methanol were purchased from B&J. Acetic acid was purchased from J.T. Baker.

Visualization of the interface of EPO and its receptor
------------------------------------------------------

To get detailed information on the interface of EPO and its receptor, a visualization tool was developed using ESBTL and OpenGL libraries. Residue information including geometry, chains, and amino acids were extracted from a PDB file loaded with the tool of ESBTL libraries. The distance between amino acids on the interface from different chains was calculated based on the x, y, and z coordinates from the geometry information extracted. The potential amino acids interacting on the interface were visualized based on the cut-off values of the calculated distance information using OpenGL libraries. 1EER PDB file (6) was used to visualize the interface of EPO and its receptor.

Peptide mapping with trypsin
----------------------------

The protein sample (100 μg) was reduced and denatured with 1 M DTT and 6 M guanidine-HCl respectively. The denaturation of protein sample was digested with trypsin on a ratio of 1 to 20 (trypsin to protein ratio) for 4 h at 37°C. The obtained peptides were separated using reversed phase chromatography with ACQUITY UPLC system (Waters, UK) equipped with ACQUITY BEH300 C18 column (1.7 μm 2.1 × 150 mm). 10 μl of peptide solutions were injected on the column with 0.2 ml/min flow rate at the temperature of 50°C. Mobile phase A was 0.1% TFA in water and B was 0.1% TFA in ACN with a gradient of 0--50% B in 90 min. The tryptic map was generated by monitoring the absorbance of the effluent with a UV detector at 215 nm. The assignment of each peptide was based on the analysis by an online electrospray ionization mass spectrometry (Q-TOF). MS spectra were obtained with the entire 0.2 ml/min column effluent over a range of 50--3,000 in mass-to-charge ratio with the setting of collision energy at 6 V and cone voltage at 35 V. Calibration of the mass spectrometers with NaCsI was performed and \[Glu1\]-fibrinopeptide B was used in the lockspray channel. The tryptic peptides were identified using BioPharmaLynx Software (Waters, UK) and the sequences of peptides were determined using PLGS Software (Waters, UK).

RESULTS
=======

Identification of potential amino acids interacting on the interface of EPO and its receptor
--------------------------------------------------------------------------------------------

The detailed structural information on the interfaces of EPO and its receptor was visualized using ESBTL and OpenGL libraries. Two binding sites between EPO and its receptor were clearly identified and visualized ([Fig. 1](#f1-molcell-37-11-819){ref-type="fig"}). The potential amino acids interacting on the interface were also identified and highlighted in [Fig. 1](#f1-molcell-37-11-819){ref-type="fig"}. Amino acid residues localized on AB coil and helix D of EPO were identified on the binding site 1 and residues found on helices A and C of EPO were identified on the binding site 2 ([Table 1](#t1-molcell-37-11-819){ref-type="table"}). Some amino acid residues on the binding site 1 were involved in forming the hydrophobic cap of EPO which was in contact to Phe93 for its receptor by hydrophobic interactions. Two amino acid residues of EPO, Thr44, and Asn147 were known to be hydrogen-bonded with Phe93 of its receptor. Most residues of EPO on the binding site 2 were hydrophilic and forming a hydrophilic pocket flanked by three Arg residues. Potential modifications specific to the amino acid residues are listed on [Table 1](#t1-molcell-37-11-819){ref-type="table"}. Four types of common modification are possible for the residues on the interfaces, including acetylation, deamidation, sulfation, and phosphorylation.

Peptide mapping analysis of EPO
-------------------------------

In order to get detailed information on any potential modifications, peptide mapping analysis was carried out using endoprotease trypsin and subsequent separation of peptide fragments by RP-UPLC. The tryptic peptides were identified by UV monitoring and online mass spectrometry. The tryptic map was generated based on the assignment of each peptide identified.

EPO consists of 165 amino acids, and 21 peptides are expected with the digestion of trypsin. T5 peptide with Asn24/Asn38 and T9 peptide with Asn83 are expected on the glycopeptides with N-glycans. T13 peptide with Ser126 is also expected on the glycopeptides with O-glycans.

A tryptic map of rHu-EPO under reduced condition is shown in [Fig. 2](#f2-molcell-37-11-819){ref-type="fig"} along with TIC profile. The map covers the full sequences of EPO, with the exception of the small polar peptides, T7 (^53^R^53^), T18 (^151^GK^152^), and T21 (^163^TGD^165^). Therefore, the LC-MS of tryptic fragments confirmed 96.4% coverage of the primary sequence for rHu-EPO. Most amino acid residues on the binding site 1 and 2 were localized on the tryptic map besides Gly151 which was not identified. T6 and T17 peptides having most of the residues from the binding site 1 were identified at the retention time of 45.4 min and 38.0 min on the UV profile of the tryptic map respectively. T3 and T10 peptides having most of residues from the binding site 2 were identified at the retention time of 5.0 min and 9.7 min on the UV profile of the tryptic map respectively ([Table 2](#t2-molcell-37-11-819){ref-type="table"}).

Identification of modified amino acids on the interface interacting between EPO and its receptor
------------------------------------------------------------------------------------------------

The measured masses of the found tryptic peptides were compared to the theoretical masses calculated from the amino acid sequences and the differences were monitored to verify the modifications of amino acid residues on the binding sites. Two deamidated peptides originated from T6 and T17 were detected on the tryptic map during these processes. The deamidated amino acids were further localized on Asn47 and Asn147 which were located on the binding site 1.

The masses of modified T6 peptide were measured and compard to the theoretical masses calculated from the amino acid sequence. T6 peptide had the sequences of ^46^VNFYAWK^52^ having one potential deamidation site at Asn47. The expected molecular mass of T6 peptide was 926.47 Da and intact T6 peptide having the expected mass was identified at 45.5 min on the TIC profile of the tryptic map ([Fig. 3](#f3-molcell-37-11-819){ref-type="fig"} and [Table 3](#t3-molcell-37-11-819){ref-type="table"}). Deamidated T6 peptide having 927.45 Da which was about 0.98 Da larger than intact T6 peptide was identified at 44.6 min on the TIC profile of the tryptic map. The relative content of deamidated T6 peptide was 2.9% of total ([Fig. 3](#f3-molcell-37-11-819){ref-type="fig"} and [Table 3](#t3-molcell-37-11-819){ref-type="table"}).

The masses of modified T17 peptide were measured and compared to the theoretical masses calculated from the amino acid sequence. T17 peptide had the sequences of ^144^VYSNFLR^150^ having one potential deamidation site at Asn147. The expected molecular mass of T17 peptide is 897.47 Da and intact T17 peptide having the expected mass was identified at 38.2 min on the TIC profile of the tryptic map ([Fig. 4](#f4-molcell-37-11-819){ref-type="fig"} and [Table 4](#t4-molcell-37-11-819){ref-type="table"}). Deamidated T17 peptide having 898.45 Da which was 0.98 Da larger than intact T17 peptide was identified at 38.8 min on the TIC profile of the tryptic map and the relative content of deamidated T17 peptide was 4.8% of the total ([Fig. 4](#f4-molcell-37-11-819){ref-type="fig"} and [Table 4](#t4-molcell-37-11-819){ref-type="table"}).

Along with deamidation at Asn47 and Asn147, one oxidized peptide originating from T8 was also detected. The oxidized amino acids were further localized on Met54 which was located on the hydrophobic cap of the EPO.

The masses of modified T8 peptide were measured and compared to the theoretical masses calculated from the amino acid sequence. T8 peptide had the sequences of ^54^MEVGQQAVEVWQGLALLSEAVLR^76^ having one potential oxidation site at Met54. The expected molecular mass of T8 peptide is 2525.33 Da and intact T8 peptide having the expected mass was identified at 82.8 min on the TIC profile of the tryptic map ([Fig. 5](#f5-molcell-37-11-819){ref-type="fig"} and [Table 5](#t5-molcell-37-11-819){ref-type="table"}). Oxidized T8 peptide having 2541.33 Da which was about 16.00 Da larger than intact T8 peptide was identified at 79.7 min on the TIC profile of the tryptic map. The relative content of oxidized T8 peptide was 3.0% of the total ([Fig. 5](#f5-molcell-37-11-819){ref-type="fig"} and [Table 5](#t5-molcell-37-11-819){ref-type="table"}).

DISCUSSION
==========

Potential amino acid residues were visualized and identified at the interfaces of EPO and its receptor. These were localized on AB coil (residues 44 to 52) and helix D (Asn147, Arg150, Gly151, and Leu155) on the binding site 1 and found on helices A (Arg10, Val11, Arg14, and Tyr15) and C (Ser100, Arg103, and Ser104) on the binding site 2. Mutations on amino acid residues within these two binding sites of EPO prevented interac tion to it's the receptor and finally abolished erythropoietic activities of EPO ([@b1-molcell-37-11-819]; [@b7-molcell-37-11-819]; [@b9-molcell-37-11-819]). Thus, any chemical modifications on these residues which were generated during the manufacturing process of rHu-EPO may also affect the efficacy of the final product so the quality issues those modifications should be identified, well-characterized, and monitored.

In order to take a close look at potential modifications at the interfaces, we've first done peptide mapping analysis of rHu-EPO with trypsin and checked if tryptic peptides containing amino acids on the interfaces would be identified. What we found was that most amino acid residues except Gly151 on the binding sites 1 and 2 were localized on the identified tryptic peptides.

Deamidations which converted Asn to Asp were identified at two amino acid residues, Asn47 and Asn147, on the binding site 1. The relative contents of deamidated residues were in the range of 3--5% of the total, which are larger than 1% of total purity and may require detailed characterization for regulation and authorization.

Asn147 of EPO is known to be involved in hydrogen bonding to the Phe93 of its receptor ([@b12-molcell-37-11-819]). Mutational analysis showed that the mutant rHu-EPO on Asn147 to Lys (rHu-EPO\[N147K\]) reduced affinity for a receptor binding over 100-fold and *in vitro* activity over 200-fold ([@b7-molcell-37-11-819]). Deamidation on Asn147 seems to be similar effects as the mutant, rHu-EPO(N147K). Deamidation on Asn newly generated negatively charged Asp on that position. This modification may change hydrogen bonding capacity between Asn147 of EPO and Phe83 of its receptor and subsequently affect not only receptor binding activity but also *in vitro* biological activity.

Based on structural data (PDB ID code, 1EER), Asn47 of EPO seemed to be involved in hydrogen bonding to Ser91 of its receptor while the adjacent Lys45 also had the same orientation to Ser91 as Asn47. Mutational data on Asn47 was not available but the mutant rHu-EPO on Lys45 to Asp \[rHu-EPO(K45D)\] which had the same orientation to Ser91 of its receptor showed 500-fold reduced affinity for receptor binding and 5000-fold reduced *in vitro* activity. The new negatively charged Asp47 by deamidation may produce effects similarly as the mutant, rHu-EPO(K45D).

Along with deamidation, another modification, oxidation, was identified at an amino acid residue, Met54. This modification was identified when rHu-EPO was under stress at pH 9 ([@b3-molcell-37-11-819]). Met54 was placed in the hydrophobic cap of EPO. Along with Met54, several amino acid residues on the binding site 1 were involved in forming the hydrophobic cap of EPO, which consisted of Val46, Phe48, Trp51, Met54, and Leu155 of EPO. This hydrophobic cap was in contact to the Phe93 of its receptor by hydrophobic interactions. Under the stress, the compact structure of the hydrophobic cap was loosened and Met54 may be vulnerable to be oxidized. Thus, Met54 can be used for a structural indicator of EPO. The content of oxidation on Met54 can be quantified and used for monitoring the structural characteristics of EPO.

The binding of the ligand protein to the specific receptor is major mode of action for most biopharmaceutical therapies. Our studies provide a targeted method focusing on the interface between the ligand and its receptor, which is coupled with UPLC-MS application. This method may contribute a novel and valuable tool which can be used to identify modification hot-spots of protein pharmaceuticals.

The authors thank scientists at BIOnSYSTEMS, Inc. (Seoul, Korea) for assistance with UPLC / Q-TOF MS.
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###### 

Potential amino acids identified on the interface interacting between EPO and its receptors

  Binding site   EPO receptor   EPO   Potential modification                     
  -------------- -------------- ----- ------------------------ ----------------- --
  Site 1         93             PHE   44                       THR               
  92             SER            45    LYS                      Acetylation       
  93             PHE            46    VAL                                        
  91             SER            47    ASN                      Deamidation       
  93             PHE            48    PHE                                        
  33             LEU            48    PHE                                        
  34             GLU            49    TYR                      Sulfation         
  34             GLU            52    LYS                      Acetylation       
  93             PHE            147   ASN                      Deamidation       
  204            SER            150   ARG                                        
  93             PHE            151   GLY                                        
  93             PHE            155   LEU                                        
  Site 2         150            MET   10                       ARG               
  150            MET            11    VAL                                        
  150            MET            14    ARG                                        
  93             PHE            15    TYR                      Sulfation         
  91             SER            100   SER                      Phosphorylation   
  62             GLU            103   ARG                                        
  92             SER            104   SER                      Phosphorylation   

###### 

Tryptic peptide identified for rHu-EPO

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Peptide            Peptide number                                            Start   End   Expected mass (Da)   RT (MIN)   Determined mass (Da)   Intensity (counts)   Mass error (ppm)
  ------------------ --------------------------------------------------------- ------- ----- -------------------- ---------- ---------------------- -------------------- ------------------
  APPR               T1                                                        1       4     439.254              2.4        439.248                13823                −13.4

  LICDSR             T2                                                        5       10    705.348              18.0       705.345                31894                −4.0

  VLER               T3                                                        11      14    515.307              5.2        515.302                41869                −8.5

  YLLEAK             T4                                                        15      20    735.417              29.1       735.412                78761                −6.0

  EAENITTGCAEHC\     T5[\*](#tfn1-molcell-37-11-819){ref-type="table-fn"}      21      45    8700.025             41.2       8700.047               2397                 2.5
  SLNENITVPDTK                                                                                                                                                           

  VNFYAWK            T6                                                        46      52    926.465              45.5       926.461                50313                −4.3

  R                  T7                                                        53      53    174.112                                                                     

  MEVGQQAVEVW\       T8                                                        54      76    2525.331             82.8       2525.337               519433               2.5
  QGLALLSEAVLR                                                                                                                                                           

  GQALLVNSSQPW\      T9[\*](#tfn1-molcell-37-11-819){ref-type="table-fn"}      77      97    5365.126             52.4       5365.163               51575                6.9
  EPLQLHVDK                                                                                                                                                              

  AVSGLR             T10                                                       98      103   601.355              9.9        601.350                45475                −7.2

  SLTTLLR            T11                                                       104     110   802.491              41.3       802.489                103380               −3.5

  ALGAQK             T12                                                       111     116   586.344              3.6        586.339                43321                −9.2

  EAISPPDAASAA PLR   T13                                                       117     131   2411.970             36.2       2412.008               205918               15.6

  EAISPPDAASAA PLR   T13[\*\*](#tfn2-molcell-37-11-819){ref-type="table-fn"}   117     131   1464.757             36.2       1464.759               14912                1.2

  TITADTFR           T14                                                       132     139   923.471              32.7       923.467                64969                −5.2

  K                  T15                                                       140     140   146.106                                                                     

  KLFR               T15--16                                                   140     143   562.359              14.0       562.356                3445                 −4.8

  LFR                T16                                                       141     143   434.264              10.4       434.260                5578                 −8.5

  VYSNFLR            T17                                                       144     150   897.471              38.2       897.468                44547                −3.1

  GK                 T18                                                       151     152   203.127                                                                     

  LK                 T19                                                       153     154   259.190                                                                     

  LKLYTGEACR         T19--20                                                   153     162   1152.596             36.3       1152.586               1671                 −9.1

  LYTGEACR           T20                                                       155     162   911.417              25.7       911.413                46068                −4.1

  TGD                T21                                                       163     165   291.107                                                                     
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

, N-glycopeptide;

, O-glycopeptide

###### 

Identification of deamidation at Asn47 of T6 peptide

  Peptide   Peptide number   Start   End   Modifiers           Expected mMass (Da)   RT (MIN)   Determined mass (Da)   Intensity (counts)   Mass error (ppm)   \% Total
  --------- ---------------- ------- ----- ------------------- --------------------- ---------- ---------------------- -------------------- ------------------ ----------
  VNFYAWK   T6               46      52                        926.465               45.5       926.468                50313                −4.3               97.1
  VNFYAWK   T6\*             46      52    Deamidatio n N(1)   927.449               44.6       927.4479               1523                 −1.2               2.9

###### 

Identification of deamidation at Asn147 of T17 peptide

  Peptide   Peptid number   Start   End   Modifiers           Expected mass (Da)   RT (MIN)   Determined mass (Da)   Intensity (counts)   Mass error (ppm)   \% Total
  --------- --------------- ------- ----- ------------------- -------------------- ---------- ---------------------- -------------------- ------------------ ----------
  VYSNFLR   1:T017          144     150                       897.4708             38.2       897.468                44547                −3.1               95.2
  VYSNFLR   1:T017\*        144     150   Deamidatio n N(1)   898.4548             38.8       898.4493               2257                 −6.1               4.8

###### 

Identification of oxidation at Met54 of T8 peptide

  Peptide                   Peptide number   Start   End   Modifiers        Expected mass (Da)   RT (MIN)   Determined mass (Da)   Intensity (counts)   Mass error (ppm)   \% Total
  ------------------------- ---------------- ------- ----- ---------------- -------------------- ---------- ---------------------- -------------------- ------------------ ----------
  MEVGQQAVEVWQGLALLSEAVLR   1:T008           54      76                     2525.3311            82.8       2525.3334              519433               2.5                97
  MEVGQQAVEVWQGLALLSEAVLR   1:T008\*         54      76    Oxidation M(1)   2541.3259            79.7       2541.3423              15922                6.5                3
